These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 16273796)

  • 1. Assessment of systemic lupus erythematosus.
    Lam GK; Petri M
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S120-32. PubMed ID: 16273796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
    Castrejón I; Tani C; Jolly M; Huang A; Mosca M
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-85-95. PubMed ID: 25365095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set.
    Ruperto N; Ravelli A; Cuttica R; Espada G; Ozen S; Porras O; Sztajnbok F; Falcini F; Kasapcopur O; Venning H; Bica B; Merino R; Coto C; Ros J; Susic G; Gamir ML; Minden K; See Y; Uziel Y; Mukamel M; Riley P; Zulian F; Olivieri AN; Cimaz R; Girschick H; Rumba I; Cavuto S; Pistorio A; Lovell DJ; Martini A; ;
    Arthritis Rheum; 2005 Sep; 52(9):2854-64. PubMed ID: 16142708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices.
    Griffiths B; Mosca M; Gordon C
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):685-708. PubMed ID: 16150398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients.
    Harris JG; Maletta KI; Kuhn EM; Olson JC
    Clin Rheumatol; 2017 Feb; 36(2):351-359. PubMed ID: 28013435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-cultural validation of a disease-specific patient-reported outcome measure for systemic lupus erythematosus in Canada.
    Bourré-Tessier J; Clarke AE; Mikolaitis-Preuss RA; Kosinski M; Bernatsky S; Block JA; Jolly M
    J Rheumatol; 2013 Aug; 40(8):1327-33. PubMed ID: 23772082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement.
    Ruperto N; Ravelli A; Oliveira S; Alessio M; Mihaylova D; Pasic S; Cortis E; Apaz M; Burgos-Vargas R; Kanakoudi-Tsakalidou F; Norambuena X; Corona F; Gerloni V; Hagelberg S; Aggarwal A; Dolezalova P; Saad CM; Bae SC; Vesely R; Avcin T; Foster H; Duarte C; Herlin T; Horneff G; Lepore L; van Rossum M; Trail L; Pistorio A; Andersson-Gäre B; Giannini EH; Martini A;
    Arthritis Rheum; 2006 Jun; 55(3):355-63. PubMed ID: 16739203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of early neuropsychiatric events due to active disease in systemic lupus erythematosus.
    Wang M; Gladman DD; Ibañez D; Urowitz MB
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):833-7. PubMed ID: 22290935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerobic capacity correlates to self-assessed physical function but not to overall disease activity or organ damage in women with systemic lupus erythematosus with low-to-moderate disease activity and organ damage.
    Boström C; Dupré B; Tengvar P; Jansson E; Opava CH; Lundberg IE
    Lupus; 2008 Feb; 17(2):100-4. PubMed ID: 18250132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of disease activity and quality of life in systemic lupus erythematosus - New aspects.
    Yee CS; McElhone K; Teh LS; Gordon C
    Best Pract Res Clin Rheumatol; 2009 Aug; 23(4):457-67. PubMed ID: 19591777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices.
    Moore AD; Clarke AE; Danoff DS; Joseph L; Bélisle P; Neville C; Fortin PR
    J Rheumatol; 1999 Jun; 26(6):1285-90. PubMed ID: 10381044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health information technologies in systemic lupus erythematosus: focus on patient assessment.
    Tani C; Trieste L; Lorenzoni V; Cannizzo S; Turchetti G; Mosca M
    Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S54-S56. PubMed ID: 27762204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: comparison with other Asian populations.
    Joo YB; Bae SC
    Int J Rheum Dis; 2015 Feb; 18(2):117-28. PubMed ID: 25524656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis.
    Rizk A; Gheita TA; Nassef S; Abdallah A
    Int J Rheum Dis; 2012 Jun; 15(3):261-7. PubMed ID: 22212605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel, disease-specific quality-of-life instrument for patients with SLE.
    Gladman DD
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):132-3. PubMed ID: 16932672
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage.
    Choi ST; Kang JI; Park IH; Lee YW; Song JS; Park YB; Lee SK
    Clin Exp Rheumatol; 2012; 30(5):665-72. PubMed ID: 22704691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice?
    Haq I; Isenberg DA
    Best Pract Res Clin Rheumatol; 2002 Apr; 16(2):181-94. PubMed ID: 12041948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage.
    Ruperto N; Buratti S; Duarte-Salazar C; Pistorio A; Reiff A; Bernstein B; Maldonado-Velázquez MR; Beristain-Manterola R; Maeno N; Takei S; Falcini F; Lepore L; Spencer CH; Pratsidou-Gertsi P; Martini A; Ravelli A
    Arthritis Rheum; 2004 Jun; 51(3):458-64. PubMed ID: 15188334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.